These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35903346)

  • 1. Adherence to Statin Therapy and Attainment of LDL Cholesterol Targets in an Outpatient Population of Type 2 Diabetes Patients: Analysis in the DIAbetes and LifEstyle Cohort Twente (DIALECT).
    Beernink JM; Oosterwijk MM; van Boven JFM; Heerspink HJL; Bakker SJL; Navis G; Nijboer RM; Gant CM; Haverkate H; Kruik-Kollöffel WJ; Laverman GD
    Front Pharmacol; 2022; 13():888110. PubMed ID: 35903346
    [No Abstract]   [Full Text] [Related]  

  • 2. Real-life achievement of lipid-lowering treatment targets in the DIAbetes and LifEstyle Cohort Twente: systemic assessment of pharmacological and nutritional factors.
    Gant CM; Binnenmars SH; Harmelink M; Soedamah-Muthu SS; Bakker SJL; Navis G; Laverman GD
    Nutr Diabetes; 2018 Apr; 8(1):24. PubMed ID: 29695715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical Urine Testing of Medication Adherence and Its Association With Clinical Markers in an Outpatient Population of Type 2 Diabetes Patients: Analysis in the DIAbetes and LifEstyle Cohort Twente (DIALECT).
    Beernink JM; Oosterwijk MM; Khunti K; Gupta P; Patel P; van Boven JFM; Lambers Heerspink HJ; Bakker SJL; Navis G; Nijboer RM; Laverman GD
    Diabetes Care; 2021 Jun; 44(6):1419-1425. PubMed ID: 33893164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.
    Morieri ML; Perrone V; Veronesi C; Degli Esposti L; Andretta M; Plebani M; Fadini GP; Vigili de Kreutzenberg S; Avogaro A
    Cardiovasc Diabetol; 2021 Jul; 20(1):144. PubMed ID: 34271920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia.
    Parris ES; Lawrence DB; Mohn LA; Long LB
    Diabetes Care; 2005 Mar; 28(3):595-9. PubMed ID: 15735194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between statin adherence and cholesterol level reduction from baseline in a veteran population.
    Kazerooni R; Watanabe JH; Bounthavong M
    Pharmacotherapy; 2013 Oct; 33(10):1044-52. PubMed ID: 23744794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study.
    Donnelly LA; Palmer CN; Whitley AL; Lang CC; Doney AS; Morris AD; Donnan PT
    Pharmacogenet Genomics; 2008 Apr; 18(4):279-87. PubMed ID: 18334912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS).
    Charlton-Menys V; Betteridge DJ; Colhoun H; Fuller J; France M; Hitman GA; Livingstone SJ; Neil HA; Newman CB; Szarek M; DeMicco DA; Durrington PN
    Clin Chem; 2009 Mar; 55(3):473-80. PubMed ID: 19147732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihyperlipidemic Medication Treatment Patterns and Statin Adherence Among Patients with ASCVD in a Managed Care Plan After Release of the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol.
    Bellows BK; Olsen CJ; Voelker J; Wander C
    J Manag Care Spec Pharm; 2016 Aug; 22(8):892-900. PubMed ID: 27459651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Qualitative Exploration of Barriers to Statin Adherence and Lipid Control: A Secondary Analysis of a Randomized Clinical Trial.
    Barankay I; Reese PP; Putt ME; Russell LB; Phillips C; Pagnotti D; Chadha S; Oyekanmi KO; Yan J; Zhu J; Volpp KG; Clapp JT
    JAMA Netw Open; 2021 May; 4(5):e219211. PubMed ID: 33944923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the association between medication adherence, as defined in quality measures, and disease-state control, health care utilization, and costs in a retrospective database analysis of Medicare supplemental beneficiaries using statin medications.
    Axon DR; Vaffis S; Chinthammit C; Lott BE; Taylor AM; Pickering M; Black H; Warholak T; Campbell PJ
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1529-1537. PubMed ID: 33251989
    [No Abstract]   [Full Text] [Related]  

  • 12. Management of LDL-cholesterol levels in patients with Diabetes Mellitus in Cardiology Practice: Real-life evidence of Under-treatment from the EPHESUS registry.
    Mert KU; Başaran Ö; Mert GÖ; Doğan V; Rencüzoğulları İ; Özlek B; Cinier G; Şenol U; Çelik O; Özlek E; Özdemir İH; Karadeniz FÖ; Bekar L; Aktaş M; Resulzade MM; Kalçık M; Aksan G; Akay K; Pekel N; Biteker M; Kayıkçıoğlu M
    Eur J Clin Invest; 2021 Jul; 51(7):e13528. PubMed ID: 33630348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
    Heintjes EM; Penning-van Beest FJ; Plat AW; Meerding WJ; Webb K; Sturkenboom MC; Herings RM
    Pharmacotherapy; 2012 Jul; 32(7):631-41. PubMed ID: 22760692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings.
    Peyser B; Perry EP; Singh K; Gill RD; Mehan MR; Haga SB; Musty MD; Milazzo NA; Savard D; Li YJ; Trujilio G; Voora D
    Circ Genom Precis Med; 2018 Sep; 11(9):e002228. PubMed ID: 30354330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to standard-dose or low-dose statin treatment and low-density lipoprotein cholesterol response in type 2 diabetes patients.
    de Vries FM; Voorham J; Hak E; Denig P
    Curr Med Res Opin; 2015 Dec; 31(12):2197-206. PubMed ID: 26359331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence to Statin Therapy and Attainment of LDL Cholesterol Goal Among Patients with Type 2 Diabetes and Dyslipidemia.
    Alwhaibi M; Altoaimi M; AlRuthia Y; Meraya AM; Balkhi B; Aldemerdash A; Alkofide H; Alhawassi TM; Alqasoumi A; Kamal KM
    Patient Prefer Adherence; 2019; 13():2111-2118. PubMed ID: 31853174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study identifying statin nonadherence with visit-to-visit variability of low-density lipoprotein cholesterol.
    Mann DM; Glazer NL; Winter M; Paasche-Orlow MK; Muntner P; Shimbo D; Adams WG; Kressin NR; Zhang Y; Choi H; Cabral H
    Am J Cardiol; 2013 May; 111(10):1437-42. PubMed ID: 23433758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of copayment with likelihood and level of adherence in new users of statins: a retrospective cohort study.
    Watanabe JH; Kazerooni R; Bounthavong M
    J Manag Care Pharm; 2014 Jan; 20(1):43-50. PubMed ID: 24372459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence to statins and LDL-cholesterol goal attainment.
    Chi MD; Vansomphone SS; Liu IL; Cheetham C; Green KR; Scott RD; Reynolds K
    Am J Manag Care; 2014 Apr; 20(4):e105-12. PubMed ID: 24884955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association between achieving low-density lipoprotein cholesterol (LDL-C) goal and statin treatment in an employee population.
    Burton WN; Chen CY; Schultz AB; Edington DW
    Popul Health Manag; 2010 Feb; 13(1):1-8. PubMed ID: 20158317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.